Poor
Not Aligned
Patient Risk:
Low
Summary
Multiple extracted claims are unsupported or contradicted by the provided FDA label text, particularly around dose/administration specifics and several patient-instruction/kinetics/mechanism assertions.
Category Scores
Accurate Statements
Nayzilam is a nasal spray form of midazolam.
Supported by provided label section 3 (NAYZILAM supplied as single-dose nasal spray unit containing midazolam).
Nayzilam is approved for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.
Supported by provided label section 1 (Indications and Usage).
Repeat dosing with Nayzilam is allowed after 10 minutes if needed.
Supported by provided label section 14 (Study 1 Test Dose Phase: two 5 mg doses separated by 10 minutes; and option to administer between 10 minutes and 6 hours if seizure activity persists/recurs).
Unsupported Statements
Nayzilam reaches peak plasma concentrations in about 21 minutes after administration.
No supporting pharmacokinetic peak-time information provided in the supplied label excerpts.
Nayzilam is designed for fast absorption through the nasal mucosa.
Mechanistic/absorption design language not supported by the supplied label excerpts.
Nayzilam bypasses slower oral routes.
No supporting language in the supplied label excerpts.
A stated dose for Nayzilam is 5 mg or 10 mg per nostril.
Provided label excerpts do not state 'per nostril' dosing; they specify 5 mg total per single-dose unit and describe two 5 mg doses separated by 10 minutes in study/test dosing.
Nayzilam can be given up to two doses per seizure cluster.
Not supported by the supplied label excerpts as a stated maximum per cluster.
Avoid food or drinks for 15 minutes post-dose to maintain Nayzilam efficacy.
Not supported by the supplied label excerpts.
Nayzilam can be used up to five episodes per month.
Not supported by the supplied label excerpts.
Frequent reliance on Nayzilam signals the need for neurologist review.
Not supported by the supplied label excerpts.
Contradictions
Low
AI Statement
In the FDA label, Nayzilam is designed for fast absorption through nasal mucosa, bypassing slower oral routes.
Label Reference
Provided label excerpt does not include this language; only 'Administer NAYZILAM by the nasal route only' is explicitly provided under 2.2.
Low
AI Statement
A stated dose for Nayzilam is 5 mg or 10 mg per nostril.
Label Reference
Provided label excerpt 3 states a single-dose nasal spray unit contains 5 mg midazolam; study dosing describes two 5 mg doses separated by 10 minutes rather than 'per nostril' dosing.
Important Omissions
Boxed warnings, contraindications beyond those not assessed in the extracted claims, drug interaction specifics, adverse reactions, and monitoring instructions were not evaluated because the extracted claims provided did not include those topics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most errors are documentation/label-adherence issues (unsupported or contradicted marketing/mechanism/kinetics and some dosing-context claims). However, incorrect dosing/administration descriptions (e.g., 'per nostril' and unverified dose frequency limits) could be clinically relevant if acted upon; therefore overall alignment is poor even though explicit contraindication/warning content was not directly contradicted in the extracted claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Several extracted claims are unsupported or contradicted by the supplied FDA label excerpts, especially dose/administration specificity and patient-instruction/kinetics/mechanism assertions.
Suggested Improvement
Remove or revise unsupported claims (peak concentration time, fast-absorption/bypass oral routes, food/drink restriction, monthly episode limit, neurologist review) and correct dosing language to match the label-supported description (5 mg per single-dose unit; study/test dosing uses two 5 mg doses separated by 10 minutes).